Funding
This clinical research received funding from the headquarters of the
University Advancement at the National Cheng Kung University, which is
sponsored by the Ministry of Education, Taiwan, ROC (to YFH). None of
the funding sources were involved in collecting, analysing or
interpreting data, writing the article or deciding to submit for
publication.
Keywords: ovarian neoplasms, fallopian tube neoplasms,
bevacizumab, vascular endothelial growth factor, progression, survival,
drug-related side effects and adverse reactions